Development Of New Class Of Halogenated Chromones For The Treatment Of Alzheimers Disease
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The present study was aimed to evaluate the anti-Alzheimer s activity of
newlinehalogenated chromones at different orientations. Based on molinspiration-drug
newlinelikeness properties, halogenated chromones at different orientation were selected
newlineand synthesized. The synthesized compound s structure was confirmed by IR,
newlineMASS and NMR spectroscopy. All the synthesized compounds were tested for in
newlinevitro acetylcholinesterase enzyme inhibitory activity. The result indicated that the
newlinetest compound C1 possessed good neuroprotective activity when compared to the
newlinestandard drug donepezil. Test compound C6 possessed least neuroprotective activity
newlinecompared to standard and test drug C1. Acute toxicity studies were conducted in
newlinemice by using OECD guidelines 420. The compound C1 and C6 was found that
newline2000 mg/kg was safe dose. For in vivo study of the compound C1 and C6, 200
newlinemg/kg and 400 mg/kg doses were selected for testing anti-Alzheimer s disease
newlineactivity as lower dose and higher dose respectively. In vivo studies were done for
newlinebest active compound C1 (2-chloro flavone) and least active compound C6 (4-fluro)
newlineby scopolamine (i.p.) and streptozocin (i.c.) induced learning and memory
newlineimpairment in mice. The anti-Alzheimer s disease activity was studied using passive
newlineavoidance test, elevated plus maze model, morris water maze and object recognition
newlinetest, and it showed dose dependent increase in memory. The CNS effects were
newlinestudied by using actophotometer and rotarod apparatus, there was no changes
newlineobserved in the locomotor activity between all groups. After the studies, animals
newlinewere sacrificed, blood and brain samples were collected. Biochemical parameters like
newlinecholesterol, glucose levels in blood and oxidative stress markers such as SOD,
newlineMDA, CAT, GPx, GSH and AchE in brain homogenate were measured. There is a
newlinesignificant decrease in the serum blood glucose levels with test drug C1 and C6 with
newlinescopolamine and STZ model.